LEXXW News and Press, Lexaria Bioscience Corp. Warrant From 02/15/24

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, has entered into definitive agreements. The agreements are for the purchase and sale of 1,558,443 shares of common stock (or common stock equivalents in lieu thereof) offered at $2.31 per share (or per commo...

KELOWNA, BC / ACCESSWIRE / February 15, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into definitive agreements for the purchase and sale of 1,558,443 shares of common ...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, has submitted its much-anticipated Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”). The application covers HYPER-H23-1, the company...

KELOWNA, BC / ACCESSWIRE / January 30, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX; LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that, on January 29, it submitted its much-anticipated Investigational New Drug ("IND") application with the U.S. F...

(TheNewswire) Kelowna, British Columbia – TheNewswire -- January 30, 2024 – Lexaria Bioscience Corp. (Nasdaq:LEXX ) (Nasdaq: LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that, on J...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, has released a shareholder letter from CEO Chris Bunka. In the letter, Bunka notes that near the end of 2023, 446 companies on the NASDAQ were trading under $1 and at risk of being delisted compared to almos...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today unveiled a comprehensive planned applied research program to thoroughly evaluate DehydraTECH for the improved delivery of GLP-1 drugs, designed to support prospective commercial partnering with global ...

(TheNewswire) Extensive work program designed to support commercial discussions. Kelowna, British Columbia – TheNewswire - January 16, 2024 – Lexaria Bioscience Corp. (Nasdaq:LEXX ) (Nasdaq: LEXXW) (the “Company” or “Lexaria...

(TheNewswire) Final results from a human pilot study show DehydraTECH TM -powered semaglutide outperforms Rybelsus ® : Sustained higher levels of semaglutide in blood; Better blood glucose control; Faster achievement of peak drug deli...

KELOWNA, BC / ACCESSWIRE / December 7, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that the Company's anticipated submission of an Investigational New Drug ("IND") application with the U.S. Foo...